Newsroom | 4646 results

CARLSBAD, Calif.--(BUSINESS WIRE)--Q2 2026 Earnings Release...

HOUSTON--(BUSINESS WIRE)--IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. Redefining the Therapeutic Paradigm: Generating New Human Muscle Duchenne muscular dystrophy (DMD) leads to progressive skeletal muscle loss, severe cardiac fibrosis, and premature death fr...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) wi...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the second quarter 2026 and provide a business update on Thursday, August 6, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improvin...

WOOD DALE, Illinois--(BUSINESS WIRE)--PHC Corporation of North America (PHCNA), proveedor de soluciones PHCbi para el cultivo celular y la conservación de muestras en toda América del Norte y América Latina, ha presentado una nueva serie de incubadoras de laboratorio con tecnología de humidificación híbrida activa y control mejorado de la contaminación. La nueva línea de incubadoras de CO₂ Cell-IQ® está diseñada para ofrecer mayor estabilidad ambiental en una amplia gama de aplicaciones de cult...

WOOD DALE, Illinois--(BUSINESS WIRE)--A PHC Corporation of North America (PHCNA), fornecedora das soluções PHCbi para cultura celular e preservação de amostras na América do Norte e na América Latina, lançou uma nova série de incubadoras de laboratório com tecnologia de umidificação híbrida ativa e controle aprimorado contra contaminação. A nova linha de incubadoras de CO₂ Cell-IQ® foi desenvolvida para proporcionar maior estabilidade ambiental para uma ampla gama de aplicações de cultura celul...

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health is one of 20 U.S. startups on the 2026 Forbes Next Billion-Dollar Startups list, all expected to reach a $1 billion valuation....

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the expansion of its leadership team with the appointments of Dr. Teji Singh, M.D., as Chief Medical Officer; David Chapman as Senior Vice President of Operations; Dr. Karin Lucas, Ph.D., as Vice President of Medical Affairs; and Maggie Loeffler, CPA, as Vice President of Finance & Administration. The...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced changes to its senior leadership team. Alex Kelly, currently Chief Financial Officer, has been promoted to the newly created role of Chief Operating Officer where he will oversee all key customer-facing functions. Naresh Tanna, currently Vice Preside...

BOSTON--(BUSINESS WIRE)--Liberate Bio, Inc., a biotechnology company developing genetic medicines that program immune cells directly inside the body, today announced the appointment of Steven H. Bernstein, M.D., as Chief Medical Officer, effective July 13, 2026. Dr. Bernstein joins Liberate as the company advances its myeloid-selective, liver-detargeted lipid nanoparticle platform and lead in vivo CAR-M programs toward first clinical evaluation. In this role, he will lead clinical development s...